R3X1.F OCUPHIRE PHARMA DL-0001

Healthcare Biotechnology Frankfurt Exchange
3.64 EUR
Close of Nov 12, 2026
1.46 5.40
Market cap
EUR 352M
P/E
-
P/B
10.84x
ROE
-416.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is R3X1.F undervalued?

Graham number

The Graham number of OCUPHIRE PHARMA DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OCUPHIRE PHARMA DL-0001 fundamental analysis

No fundamental analysis for OCUPHIRE PHARMA DL-0001 yet.

OCUPHIRE PHARMA DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OCUPHIRE PHARMA DL-0001

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-…

Full company profile